7
84
Korczyn & Nussbaum
8
9
. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levo-
dopa on catecholamine- rich neurons. Mov Disord 1992; 7:
3-31
. Brucke T, Asenbaum S, Pirker W, et al. Measurement of the
dopaminergic degeneration in Parkinson’s disease with
28. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and
psychiatric side effects in the treatment of Parkinson’s dis-
ease. Neurology 1993; 43: S47-52
29. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-
induced hallucinations in parkinsonian patients. Neurology
1998; 51: 811-4
30. Nausieda PA, Weiner WJ, Kaplan LR, et al. Sleep disruption in
the course of chronic levodopa therapy: an early feature of the
levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-94
2
[
123]β-CIT and SPECT. Correlation with clinical findings
and comparison with multiple system atrophy and progressive
supranuclear palsy. J Neural Transm Suppl. 1997; 50: 9-24
1
0. Brooks DJ. Advances in imaging Parkinson’s disease. Curr
Opin Neurol 1997; 10: 327-31
3
1. Ferreira JJ, Thalamas C, Montastruc JL, et al. Levodopa mono-
therapy can induce ‘sleep attacks’ in Parkinson’s disease pa-
tients. J Neurol 2001; 248: 426-7
11. Nurmi E, Ruottinen HM, Kaasinen V, et al. Progression in Par-
kinson’s disease: a positron emission tomography study with
a dopamine transporter ligand [18F]CFT. Ann Neurol 2000;
3
2. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the
wheel: motor vehicle mishaps in persons taking pramipexole
and ropinirole. Lancet 2000; 355: 1332-3
4
7: 804-8
1
2. Trugman JM, Hubbard CA, Bennett Jr JP. Dose-related effects
of continuous levodopa infusion in rats with unilateral lesions
of the substantia nigra. Brain Res 1996; 725: 177-83
3. Korczyn AD, Nisipeanu P. Newer therapies for Parkinson’s dis-
ease. Neurol Neurochir Pol 1996; 30 Suppl. 2: 105-11
4. Jenner P. The rationale for the use of dopamine agonists in Par-
kinson’s disease. Neurology 1995; 45 (3 Suppl. 3) s6-12
5. Watts RL. The role of dopamine agonists in early Parkinson’s
disease. Neurology 1997; 49: S34-48
3
3
3
3. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes
in Parkinson’s disease. Mov Disord 2000; 15: 212-5
4. Ryan M, Slevin JT, Wells A. Non-ergot dopamine agonists-in-
duced sleep attacks. Pharmacotherapy 2000; 6: 724-6
5. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericar-
ditis and pleuropulmonary disease linked to ergot dopamine
agonist therapy (cabergoline) for Parkinson’s disease. Mayo
Clin Proc 1999; 74: 371-5
1
1
1
1
6. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson’s
disease should begin with a dopamine agonist. Mov Disord
3
3
3
6. Bressman SB, Shulman LM, Tanner CM, et al. Long-term
safety and efficacy of pramipexole in early Parkinson’s dis-
ease [abstract]. Neurology 1999; 52 Suppl. 2: A261
7. Roberts JW, Maral Mouradian M, Ho Sohn Y, et al. D2 agonist
N-0923 treatment of Parkinson’s disease [abstract]. Neurol-
ogy 1994; 44 Suppl. 2: 244
8. Hutton JT, Chase T, Verhagen L, et al. Transdermal dopamine
D2 receptor agonist therapy with N-0923 TDS in Parkinson’s
isease: a double-blind, placebo-controlled study [abstract].
Mov Disord 1988; 13 Suppl. 2: 62
1
999; 14: 725-30
1
7. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of
the incidence of dyskinesia in patients with early Parkinson’s
disease who were treated with ropinirole or levodopa. 056
Study Group. N Engl J Med 2000; 342 (20): 1484-91
8. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients
with early Parkinson’s disease. Clin Neuropharmacol 1995;
1
1
2
1
8: 338-47
9. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized
trial of ropinirole and bromocriptine in early Parkinson’s dis-
ease. Neurology 1999; 53: 364-70
0. Bodde HE, Van Laar T, Van der Geest R, et al. An integrated
pharmacokinetic- pharmacodynamic approach to optimiza-
tion of R-apomorphine delivery in Parkinson’s disease. Adv
Drug Deliv Rev 1998; 33: 253-63
1. Ondo W, Hunter C, Almaguer M, et al. A novel sublingual apo-
morphine treatment for patients with fluctuating Parkinson’s
disease. Mov Disord 1999; 14: 664-8
2. Montastruc JL, Rascol O, Senard JM, et al. Sublingual apomor-
phine: a new pharmacological approach in Parkinson’s dis-
ease? J Neural Transm Suppl. 1995; 45: 157-61
3
4
9. Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue
therapy for response fluctuations in Parkinson’s disease. Ann
Neurol 1996; 39: 400-4
0. Djaldetti R, Giladi N, Peretz-Aharon Y, et al. Oral levodopa
ethylester (LDEE) for treatment of response fluctuations in
patients with advanced Parkinson’s disease: results of a dou-
ble-blind controlled study [abstract]. Mov Disord 1998; 13
Suppl. 2: 58
2
2
2
4
4
4
1. Rascol O, Blin O, Thalamas C, et al. ABT-431, a D1 receptor
agonist prodrug has efficacy in Parkinson’s disease. Ann Neu-
rol 1999; 45: 736-41
2. Uchiumi M, Ochiai K, Nakano T, et al. Phase I study of BAM-
1110: single and repeated administration [abstract]. Mov Dis-
3. Ikechukwu Ugwoke M, Kaufmann G, Verbeke N, et al. Intra-
nasal bioavailability of apomorphine from carboxymethyl-
cellulose-based drug delivery systems. Int J Pharm 2000; 202:
ord 1996; 11 Suppl. 1: 163
3. Doll MK, Nichols DE, Kilts JD, et al. Synthesis and dopamin-
ergic properties ofbenzo-fused analogues of quinpirole and
quinelorane. J Med Chem 1999; 42 (5): 935-40
1
25-31
2
2
4. Corboy DL, Wagner ML, Sage JI. Apomorphine for motor fluc-
tuations and freezing in Parkinson’s disease. Ann Phar-
macother 1995; 29: 282-8
5. Korczyn AD. Autonomic nervous system disturbances in Par-
kinson’s disease. In: MB Streifler, AD Korczyn, E Melamed,
et al., editors. Advances in neurology: Parkinson’s disease:
anatomy, pathology, therapy. New York: Raven Press, 1990:
44. Ghosh D, Snyder SE, Watts VJ, et al. 9-Dihydroxy-2,3,7,11b
-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full do-
pamine D1 agonist containing a rigid-beta-phenyldopamine
pharmacophore. J Med Chem 1996; 39 (2): 549-55
45. Kaakkola S. Clinical pharmacology, therapeutic use and poten-
tial of COMT inhibitors in Parkinson’s disease. Drugs 2000;
59 (6): 1233-50
4
63-68
2
2
6. Kujawa KA, Leurgans S, Raman R, et al. Dopamine agonists
and orthostatic hypotension in Parkinson’s disease [abstract].
Neurology 1999; 52 Suppl. 2: A407
7. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psy-
chosis: a kindling phenomenon. Am J Psychiatry 1978; 135:
46. Bonifati V, Meco G. New, selective catechol-O-methyl-
transferase inhibitors as therapeutic agents in Parkinson’s dis-
ease. Pharmacol Ther 1999; 81 (1): 1-36
47. Kurth MC, Adler CH. COMT inhibition: a new treatment strat-
egy for Parkinson’s disease. Neurology 1998; 50 (5 Suppl. 5):
S3-14
6
69-75
©
Adis International Limited. All rights reserved.
Drugs 2002; 62 (5)